

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
Cytokinetics, Incorporated	12/29/2006

RECEIVING PARTY DATA

Name:	Amgen, Inc.
Street Address:	One Amgen Center Drive
City:	Thousand Oaks
State/Country:	CALIFORNIA
Postal Code:	91320-1799

PROPERTY NUMBERS Total: 40

Property Type	Number
Patent Number:	6908923
Patent Number:	7053094
Application Number:	60343092
Application Number:	10327252
Application Number:	60343126
Application Number:	60343089
Application Number:	60343088
Application Number:	11353252
Application Number:	60342965
Application Number:	60445221
Application Number:	60458702
Application Number:	10550398
Application Number:	60440133
Application Number:	60476517
Application Number:	60501376

CH \$1600.00 6908923

Application Number:	11032227
Application Number:	10541596
Application Number:	60440183
Application Number:	60476086
Application Number:	10890829
Application Number:	60548678
Application Number:	60569021
Application Number:	60581197
Application Number:	60662103
Application Number:	60756356
Application Number:	11155940
Application Number:	60591338
Application Number:	60591525
Application Number:	60616341
Application Number:	60705848
Application Number:	60751123
Application Number:	11498986
Application Number:	60751841
Application Number:	60750901
Application Number:	60750986
Application Number:	60751252
Application Number:	60751118
Application Number:	60751032
Application Number:	60751400
Application Number:	60817975

CORRESPONDENCE DATA

Fax Number: (212)446-4900
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 2129093078
Email: szablocki@kirkland.com
Correspondent Name: Kirkland & Ellis LLP; Att: Susan Zablocki
Address Line 1: 153 East 53rd Street
Address Line 4: New York, NEW YORK 10022

ATTORNEY DOCKET NUMBER:	41466-1
NAME OF SUBMITTER:	Susan Zablocki

Total Attachments: 11

source=Amgen CK Patent Security Agreement#page1.tif
source=Amgen CK Patent Security Agreement#page2.tif
source=Amgen CK Patent Security Agreement#page3.tif
source=Amgen CK Patent Security Agreement#page4.tif
source=Amgen CK Patent Security Agreement#page5.tif
source=Amgen CK Patent Security Agreement#page6.tif
source=Amgen CK Patent Security Agreement#page7.tif
source=Amgen CK Patent Security Agreement#page8.tif
source=Amgen CK Patent Security Agreement#page9.tif
source=Amgen CK Patent Security Agreement#page10.tif
source=Amgen CK Patent Security Agreement#page11.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Patent Security Agreement") is made and entered into as of December 29th, 2006 (the "Effective Date") by and between Cytokinetics, Incorporated, a Delaware corporation (including its successors and assigns, "Grantor"), and Amgen Inc., a Delaware corporation (including its successors and assigns, "Grantee").

WITNESSETH:

WHEREAS, Grantor and Grantee are parties to that certain Security Agreement, dated of even date herewith (as amended, supplemented and otherwise modified from time to time, the "Security Agreement"); and

WHEREAS, pursuant to the Security Agreement, Grantor is required to execute and deliver to Grantee this Patent Security Agreement for the purposes of filing.

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows.

1. **DEFINED TERMS.** All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement or Collaboration and Option Agreement.

2. **GRANT OF SECURITY INTEREST IN PATENT COLLATERAL.** Grantor hereby grants to Grantee a continuing first priority security interest in all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral"):

(a) the CK Patent Rights, including all of the patents and patent applications set forth on Schedule I hereto;

(b) all issued patents, reissues, reexaminations, renewals, and extensions of the foregoing and any continuations, continuations-in-part or divisionals of the foregoing;

(c) all rights to sue for past, present and future infringement of any such patent right, including the right to receive all income, royalties and damages therefrom; and

(d) to the extent not otherwise included, all products and proceeds of the foregoing.

3. **SECURITY FOR OBLIGATIONS.** This Patent Security Agreement and the security interest created hereby secures the performance of all the Secured Obligations, whether now existing or arising hereafter.

4. **SECURITY AGREEMENT.** The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Grantee pursuant to the Security Agreement. Grantor hereby acknowledges and affirms that the

rights and remedies of Grantee with respect to the security interest in the Patent Collateral set forth herein are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

5. **AUTHORIZATION TO SUPPLEMENT.** Grantor shall give Grantee prompt notice in writing of any additional patents or applications therefor after the date hereof that are included in the Patent Collateral. Grantor hereby authorizes Grantee unilaterally to modify this Agreement by amending Schedule I to include any such future patents or applications therefor of Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Grantee's continuing security interest in all Patent Collateral, whether or not listed on Schedule I.

Confidential

IN WITNESS WHEREOF, the parties have executed this Patent Security Agreement as of the date first set forth above.

CYTOKINETICS, INCORPORATED

AMGEN INC.

By: 

By: _____

Name: Robert I Blum

Name: Richard D. Nanula

Title: President

Title: Executive Vice President
& Chief Financial Officer

Approved

Legal

MW
12/29/06

**SIGNATURE PAGE TO CYTOKINETICS, INCORPORATED
PATENT SECURITY AGREEMENT**

Amgen Contract No. 200625174

**PATENT
REEL: 018700 FRAME: 0109**

Confidential



IN WITNESS WHEREOF, the parties have executed this Patent Security Agreement as of the date first set forth above.

CYTOKINETICS, INCORPORATED

By: _____

Name: _____

Title: _____

AMGEN INC.

By: _____

Name: Richard D. Nanula

Title: Executive Vice President
& Chief Financial Officer

**SIGNATURE PAGE TO CYTOKINETICS, INCORPORATED
PATENT SECURITY AGREEMENT**

Amgen Contract No. 200625174

**PATENT
REEL: 018700 FRAME: 0110**

SCHEDULE I
TO
PATENT SECURITY AGREEMENT

PATENT COLLATERAL

US APPLICATIONS / PATENTS

REF. NO.	APPLN. NO.	FILING DATE	TITLE	STATUS
1076PPRO	60/343,092	12/21/01	Compositions and methods for treating heart failure	Expired
1076	10/327,252 2003-0158186	12/20/02	Compositions and methods for treating heart failure	Abandoned
1077PRO	60/343,126	12/21/01	Compositions and methods for treating heart failure	Expired
1078PRO	60/343,089	12/21/01	Compositions and methods for treating heart failure	Expired
1079PRO	60/343,088	12/21/01	Compositions and methods for treating heart failure	Expired
1079.1	10/327,219 6,908,923	12/20/02	Compositions and methods for treating heart failure	Issued
1079.1A	11/040,478 7,053,094	01/20/05	Compositions and methods for treating heart failure	Issued
1079.1B	11/353,252 2006-0173024	02/13/06	Compositions and methods for treating heart failure	Pending
1080PRO	60/342,965	12/21/01	Compositions and methods for treating heart failure	Expired
1123PRO	60/445,221	02/04/03	Compositions and methods for treating heart failure	Expired
1128PRO	60/458,702	03/27/03	Compositions and methods for treating heart failure	Expired
1128US	10/550,398	From PCT	Compositions and methods for treating heart failure	1128US
1130PRO	60/440,133	01/14/03	Compositions and methods for treating heart failure	Expired
1130PRO2	60/476,517	06/05/03	Compositions and methods for treating heart failure	Expired
1130PRO3	60/501,376	09/08/03	Compositions and methods for treating heart failure	Expired
1130.1	11/032,227 2006-0025470	01/11/05	Compounds, Compositions and Methods	Allowed
1130US	10/541,596 US 2006-0241110	From PCT	Compounds, Compositions and Methods	Pending
1141PRO	60/440,183	01/14/03	Compositions and methods for treating heart failure	Expired

REF. NO.	APPLN. NO.	FILING DATE	TITLE	STATUS
1141PRO2	60/476,086	06/04/03	Compositions and methods for treating heart failure	Expired
1207	10/890,829 2005-0159416	07/14/04	Compounds, Compositions and Methods	Pending
1209PRO	60/548,678	02/26/04	Compounds, Compositions and Methods	Expired
1209PRO2	60/569,021	05/07/04	Compounds, Compositions and Methods	Expired
1211PRO	60/581,197	06/17/04	Compounds, Compositions and Methods	Expired
1211PRO2	60/662,103	03/14/05	Compounds, Compositions and Methods	Expired
12111PRO3	60/756,356	01/04/06	Compounds, Compositions and Methods	Pending
1211	11/155,940 2006-0014761	06/16/05	Compounds, Compositions and Methods	Pending
1215PRO	60/591,338	07/27/04	Synthesis of Ureas	Expired
1216PRO	60/591,525	07/27/04	Synthesis of Ureas	Expired
1215PRO2	60/616,341	10/05/04	Synthesis of Ureas	Expired
1222PRO	60/705,848	08/04/05	Compounds, Compositions and Methods	Expired
1222PRO2	60/751,123	12/16/05	Compounds, Compositions and Methods	Expired
1222	11/498,986	08/04/06	Compounds, Compositions and Methods	Pending
1232PRO	60/751,841	12/19/05	Compounds, compositions, and methods	Expired
1232	TBD	12/14/06	Compounds, Compositions and Methods	Pending
1233PRO	60/750,901	12/15/05	Certain chemical entities, compositions, and methods	Expired
1233	TBD	12/13/06	Certain chemical entities, compositions, and methods	Pending
1234PRO	60/750,986	12/15/05	Certain chemical entities, compositions and methods	Expired
1234	TBD	12/13/06	Certain chemical entities, compositions, and methods	Pending
1235PRO	60/751,252	12/15/05	Certain novel forms of compounds, compositions, and methods	Expired
1235	TBD	12/14/06	Certain novel forms of compounds, compositions, and methods	Pending
1236PRO	60/751,118	12/16/05	Certain chemical entities, compositions and methods	Expired
1236	TBD	12/13/06	Certain chemical entities, compositions and methods	Pending
1251PRO	60/751,032	12/16/05	Certain chemical entities, compositions and methods	Expired
1251	TBD	12/13/06	Certain chemical entities, compositions and methods	Pending
1252PRO	60/751,400	12/15/05	Compounds, compositions, and methods	Expired
1252PRO2	60/817,975	06/29/06	Compounds, compositions, and methods	Pending
1252	TBD	12/14/06	Compounds, compositions, and methods	Pending

FOREIGN APPLICATIONS

REF. NO.	COUNTRY	APPLN. NO.	FILING DATE	TITLE	STATUS
1076PCT	PCT	US02/41309 WO 03/59265	12/20/02	Compositions and methods for treating heart failure	Did not enter national phase
1079PCT	PCT	PCT/US02/40996 WO 03/059258	12/20/02	Compositions and methods for treating heart failure	Entered national phase
1079CA	Canada	2470427	From PCT	Compositions and methods for treating heart failure	Pending
1079EP	Europe	02 806 491.3	From PCT	Compositions and methods for treating heart failure	Pending
1128PCT	PCT	PCT/US04/09408 WO 2004/86865	03/26/04	Compositions and methods for treating heart failure	Entered national phase
1128EP	Europe	04 758456	From PCT	Compositions and methods for treating heart failure	Pending
1130PCT	Canada	PCT/US04/01069 WO 2004/064730	01/14/04	Compositions and methods for treating heart failure	Entered national phase
1130AU	Australia	2004206860	From PCT	Compounds, Compositions and Methods	Pending
1130CA	Canada	2511970	From PCT	Compounds, Compositions and Methods	Pending
1130CN	China	200480002177	From PCT	Compounds, Compositions and Methods	Pending
1130EP	Europe	04702228.0	From PCT	Compounds, Compositions and Methods	Pending
1130HK	Hong Kong	06105587.2	From PCT	Compounds, Compositions, and Methods	Pending
1130IN	India	3136/DELNP/2005	From PCT	Compounds, Compositions and Methods	Pending
1130KR	South Korea	10-2005-7013092	From PCT	Compounds, Compositions and Methods	Pending
1130MX	Mexico	PA/a/2005/007513	From PCT	Compounds, Compositions and Methods	Pending

REF. NO.	COUNTRY	APPLN. NO.	FILING DATE	TITLE	STATUS
1130NZ	New Zealand	540878	From PCT	Compounds, Compositions and Methods	Pending
1130PH	Philippines	1-2005-501298	From PCT	Compounds, Compositions and Methods	Pending
1130SG	Singapore	200503965-6	From PCT	Compounds, Compositions and Methods	Pending
1211PCT	PCT	PCT/US05/21100 WO 2006/009726	06/16/05	Compounds, Compositions and Methods	Entered national phase
1211AL	Algeria	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211AR	Argentina	P050102494	06/17/05	Compounds, Compositions and Methods	Pending
1211AU	Australia	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211BR	Brazil	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211CA	Canada	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211CN	China	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211CL	Chile	2005-1503	06/17/05	Compounds, Compositions and Methods	Pending
1211CO	Colombia	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211EG	Egypt	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211EP	Europe	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211GC	Gulf Cooperation Council	GCC/P/2005/4798	06/18/05	Compounds, Compositions and Methods	Pending

REF. NO.	COUNTRY	APPLN. NO.	FILING DATE	TITLE	STATUS
1211ID	Indonesia	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211IL	Israel	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211IN	India	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211KR	South Korea	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211MO	Morocco	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211MT	Malta	2840	06/16/05	Compounds, Compositions and Methods	Pending
1211MX	Mexico	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211MY	Malaysia	PI 20052761	06/16/05	Compounds, Compositions and Methods	Pending
1211NG	Nigeria	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211NO	Norway	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211NZ	New Zealand	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211PE	Peru	000695-2005	TBD	Compounds, compositions, and methods	Pending
1211PH	Philippines	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211PK	Pakistan	544/2005	06/14/05	Compounds, Compositions and Methods	Pending
1211PL	Poland	TBD	From PCT	Compounds, Compositions and Methods	Pending

REF. NO.	COUNTRY	APPLN. NO.	FILING DATE	TITLE	STATUS
1211RU	Russia	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211SG	Singapore	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211VN	Viet Nam	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211TH	Thailand	101528	06/16/05	Compounds, Compositions and Methods	Pending
1211TT	Trinidad & Tobago	TBD	From PCT	Compounds, Compositions and Methods	Pending
1211TW	Taiwan	94119915	06/16/05	Compounds, Compositions and Methods	Pending
1211VE	Venezuela	1223/2005	06/17/05	Compounds, Compositions and Methods	Pending
1211ZA	South Africa	TBD	From PCT	Compounds, Compositions and Methods	Pending
1232PCT	PCT	TBD	12/14/06	Compounds, Compositions and Methods	Pending
1233PCT	PCT	TBD	12/13/06	Certain chemical entities, compositions, and methods	Pending
1234PCT	PCT	TBD	12/13/06	Certain chemical entities, compositions, and methods	Pending
1235PCT	PCT	TBD	12/14/06	Certain novel forms of compounds, compositions, and methods	Pending
1236PCT	PCT	TBD	12/13/06	Certain chemical entities, compositions and methods	Pending
1251PCT	PCT	TBD	12/13/06	Certain chemical entities, compositions and methods	Pending
1252PCT	PCT	TBD	12/14/06	Compounds, compositions, and methods	Pending

REF. NO.	COUNTRY	APPLN. NO.	FILING DATE	TITLE	STATUS
1252AR	Argentina	TBD	12/15/06	Compounds, compositions, and methods	Pending
1252CL	Chile	TBD	TBD	Compounds, compositions, and methods	Pending
1252MT	Malta	TBD	TBD	Compounds, compositions, and methods	Pending
1252PE	Peru	TBD	TBD	Compounds, compositions, and methods	Pending
1252PK	Pakistan	TBD	TBD	Compounds, compositions, and methods	Pending
1252TW	Taiwan	TBD	TBD	Compounds, compositions, and methods	Pending
1252TH	Thailand	TBD	TBD	Compounds, compositions, and methods	Pending
1252VE	Venezuela	TBD	TBD	Compounds, compositions, and methods	Pending
1252GCC	Gulf Cooperation Council	TBD	TBD	Compounds, compositions, and methods	Pending